2020
DOI: 10.3390/jpm11010007
|View full text |Cite
|
Sign up to set email alerts
|

Gene Editing Targeting the DUX4 Polyadenylation Signal: A Therapy for FSHD?

Abstract: Facioscapulohumeral dystrophy (FSHD, OMIM: 158900, 158901) is the most common dystrophy in adults and so far, there is no treatment. Different loci of the disease have been characterized and they all lead to the aberrant expression of the DUX4 protein, which impairs the function of the muscle, ultimately leading to cell death. Here, we used gene editing to try to permanently shut down DUX4 expression by targeting its poly(A) sequence. We used transcription activator-like effector nucleases (TALEN) and CRISPR-C… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
16
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 14 publications
(17 citation statements)
references
References 33 publications
(51 reference statements)
1
16
0
Order By: Relevance
“…One obvious advantage over murine transgenic models is that human-to-mouse muscle xenografts are comprised almost exclusively of human tissue and thus provide the best source of mature human muscle, outside of the clinic, to study the specificity and efficacy of drugs designed to treat FSHD. In particular, xenograft models of FSHD are the only setting in which therapeutic approaches targeting the FSHD locus and DUX4 epigenetic or transcriptional regulation [ 157 , 159 , 160 , 161 , 162 , 163 , 164 , 165 ] can be tested in vivo.…”
Section: Animal Models Of Fshdmentioning
confidence: 99%
“…One obvious advantage over murine transgenic models is that human-to-mouse muscle xenografts are comprised almost exclusively of human tissue and thus provide the best source of mature human muscle, outside of the clinic, to study the specificity and efficacy of drugs designed to treat FSHD. In particular, xenograft models of FSHD are the only setting in which therapeutic approaches targeting the FSHD locus and DUX4 epigenetic or transcriptional regulation [ 157 , 159 , 160 , 161 , 162 , 163 , 164 , 165 ] can be tested in vivo.…”
Section: Animal Models Of Fshdmentioning
confidence: 99%
“…Some experiments were conducted using gene editing to try to permanently shut down DUX4 expression by targeting its poly(A) sequence. The results suggest that targeting the DUX4 poly(A) signal to destroy the PAS is possible to some extent [ 25 ], hence a more effective method needs further studies. Single nucleotide exchanges within the hexamer are known to interfere tremendously with mRNA processing and cause a range of diseases.…”
Section: Introductionmentioning
confidence: 99%
“…While several reports have proposed the administration of chemical compounds aimed at RNA interference [15][16][17][18] or blocking signal transduction 19 with promising results to reduce DUX4 activity, the effects of these strategies always depend on continuous treatment due to chemical instability and may force patients to semi-permanent frequent drug administration. Genome editing, however, provides an option to achieve permanent transcriptional repression, but some reports have shown skeptical results after the removal of PAS on 4qA due to stochastic effects and layered of efficiency issues, including delivery, binding, and rewriting as desired 20,21 . The targeting of the DUX4 gene body or promoter is still difficult to control as it is located inside a repetitive D4Z4 unit.…”
Section: Introductionmentioning
confidence: 99%